Dr. Robert Pierce former MRK senior R&D and Clinical Trial specialist knows exactly the synergy there would be with the Combo and exactly the reason he left MRK to join $ONCS where he is now CSO.
Dr. Pierce's goal from the beginning was a Combo IL12+Keytruda via EP treatment. $ONCS's 1200 to 1400 watts EP opens up the cancer's protective walls forcing immunogenicity factors to enter and transmit messengers back to one's body central control that then send out NK cells to destroy cancer the enemy.
$ONCS EP+IL12 is a producer of CD8 TILs, immunogenicity biologic component. The EP would also increase the penetration of Keytruda. Thereby the immunogenicty factors working in synchronous harmony producing more NKs resulting in increased ORR destroying more cancer than either IL12 or Keytruda alone. For Dr. Pierce a dream fruition materializing.
News 
Market Data 
Discover 
